Clinical Trials
28 trialsClofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
Eastern Cooperative Oncology Group
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Eastern Cooperative Oncology Group
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Children's Oncology Group
Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
Eastern Cooperative Oncology Group
Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531
Children's Oncology Group
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy
SWOG Cancer Research Network
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
SWOG Cancer Research Network
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
SWOG Cancer Research Network
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
SWOG Cancer Research Network
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
SWOG Cancer Research Network
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
SWOG Cancer Research Network
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia
SWOG Cancer Research Network
S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia
SWOG Cancer Research Network
S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia
SWOG Cancer Research Network
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
SWOG Cancer Research Network
S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia
SWOG Cancer Research Network
AML-17
European Organisation for Research and Treatment of Cancer - EORTC
AML-19
European Organisation for Research and Treatment of Cancer - EORTC
AML-14A
European Organisation for Research and Treatment of Cancer - EORTC
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
European Organisation for Research and Treatment of Cancer - EORTC